The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
T-cells: The Key To Unlocking Immunity Against Aggressive Lymphoma
Funder
National Health and Medical Research Council
Funding Amount
$322,951.00
Summary
By investigating several aspects of patients’ immune defenses against the cancer cells in Diffuse large B-cell lymphoma, this project will provide critical insights on ways to harness the patient’s own immune system to effectively mount anti-tumour responses. These results will pave the way for future therapeutic strategies to successfully treat and prevent lymphoma.
Molecular Regulation Of Tim3 Signalling In T Cells
Funder
National Health and Medical Research Council
Funding Amount
$366,252.00
Summary
Chronic inflammatory diseases like multiple sclerosis and cancer can be rectified via interventions of T cell checkpoint pathway. Tim3 is a T cell checkpoint molecule that is gaining extreme interest in these diseases. Here, we aim to identify molecular mechanism(s) to suppress or enhance Tim3 signalling in effector T cell, potentially leading to the development of therapeutic intervention to treat autoimmune disorders and cancers.
Investigation Of Unique Immune Microenvironment Of Primary CNS Lymphoma
Funder
National Health and Medical Research Council
Funding Amount
$265,138.00
Summary
This study will investigate how the immune system responds to the development of brain lymphoma. It is expected that this lymphoma develops due to a defective immune response. It is unknown why the tumour is so effective at evading the immune response but if the hypothesis is correct, then the application of new drugs that stimulate the immune system to attack the lymphoma could lead to a marked improvement in survival without the need for toxic chemotherapy and radiation.